COST-EFFECTIVENESS OF NIVOLUMAB IN PATIENTS WITH PRE-TREATED ADVANCED RENAL CELL CARCINOMA (ARCC) IN THE UNITED STATES: IMPACT OF > 5 YEARS OF FOLLOW-UP DATA FROM CHECKMATE 025-MedSci.cn

COST-EFFECTIVENESS OF NIVOLUMAB IN PATIENTS WITH PRE-TREATED ADVANCED RENAL CELL CARCINOMA (ARCC) IN THE UNITED STATES: IMPACT OF > 5 YEARS OF FOLLOW-UP DATA FROM CHECKMATE 025

May, J; Malcolm, B; Ejzykowicz, F; Kurt, M; Borrill, J; Theriou, C; Teitsson, S

VALUE IN HEALTH, 2020; 23 (): S523

科室
- - 订阅+
  - 更多科室
工具
服务